Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.49 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.47 |
| ▸ | TP53 | P04637 | 4/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.45 |
| ▸ | HPGD | P15428 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 2/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | MPO | P05164 | 2/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29483355 | 0.90 | KDM4E (0.54) | SMN1; SMN2P2RX7KDM4EHPGDMAPT | |
| SCHEMBL201295 | 0.81 | LMNA (0.51) | SMN1; SMN2P2RX7TP53KDM4EHPGD | |
| SCHEMBL12713296 | 0.79 | KDM4E (0.49) | SMN1; SMN2KDM4EHPGDALDH1A1MAPK1 | |
| SCHEMBL6312839 | 0.79 | ALDH1A1 (0.64) | SMN1; SMN2TP53KDM4EHPGDMAPT | |
| SCHEMBL729049 | 0.77 | GAA (0.47) | SMN1; SMN2KDM4EHPGDMAPTALDH1A1 | |
| SCHEMBL7141381 | 0.77 | SMN1; SMN2 (0.49) | SMN1; SMN2P2RX7TP53KDM4EHPGD | |
| SCHEMBL19293621 | 0.76 | SMN1; SMN2 (0.62) | SMN1; SMN2TP53KDM4EHPGDMAPT | |
| SCHEMBL27549630 | 0.74 | KDM4C (0.43) | SMN1; SMN2TP53KDM4EHPGDMAPT | |
| SCHEMBL27549823 | 0.74 | SMN1; SMN2 (0.49) | SMN1; SMN2P2RX7TP53KDM4EHPGD | |
| SCHEMBL17595399 | 0.74 | MAPT (0.68) | SMN1; SMN2TP53KDM4EMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220402883-A1 | COMPOUNDS AND METHODS FOR MODULATING RNA FUNCTION | ARRAKIS THERAPEUTICS, INC. | 2022-12-22 | — | — | US | disclosed |
| US-20220281860-A1 | COMPOUNDS AND METHODS OF TREATING RNA-MEDIATED DISEASES | ARRAKIS THERAPEUTICS, INC. | 2022-09-08 | — | — | US | disclosed |
| US-6642234-B1 | Insecticides, acaricides, nematocides, herbicides and fungicides, | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2003-11-04 | — | — | US | disclosed |
| EP-1142882-A9 | ACRYLONITRILE COMPOUNDS | Nissan Chemical Industries, Ltd. (JP) | 2002-10-02 | — | — | EP | disclosed |
| CN-1333759-A | Acrylonitrile compounds | NISSAN CHEMICAL IND LTD (JP) | 2002-01-30 | — | — | CN | disclosed |
| EP-1142882-A1 | ACRYLONITRILE COMPOUNDS | Nissan Chemical Industries, Ltd. (JP) | 2001-10-10 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220281860-A1 | COMPOUNDS AND METHODS OF TREATING RNA-MEDIATED DISEASES | NSUN3, NSUN2, POLRMT | SMN1; SMN2 145/4885P2RX7 3210/4885TP53 507/4885 |
| US-20220402883-A1 | COMPOUNDS AND METHODS FOR MODULATING RNA FUNCTION | NSUN3, NSUN2, METTL16 | SMN1; SMN2 917/4885P2RX7 2852/4885TP53 825/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.